Atea Pharmaceuticals (AVIR) Change in Accured Expenses (2019 - 2026)

Atea Pharmaceuticals' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$2.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 880.69% year-over-year to -$2.7 million; the TTM figure through Mar 2026 stood at $9.6 million (up 282.45% YoY), while the FY2025 annual figure was $12.7 million, up 194.26% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$2.7 million, down from $9.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $9.8 million in Q4 2023, with the low at -$28.0 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is $347000.0 (2025), against an average of -$1.7 million.
• The sharpest annual moves came in 2023 and 2026: Change in Accured Expenses soared 556.59% in 2023, then tumbled 880.69% in 2026.
• Atea Pharmaceuticals' Change in Accured Expenses stood at $1.5 million in 2022, then jumped by 556.59% to $9.8 million in 2023, then tumbled by 152.42% to -$5.1 million in 2024, then surged by 290.21% to $9.7 million in 2025, then plunged by 127.84% to -$2.7 million in 2026.
• Business Quant data shows AVIR's Change in Accured Expenses at -$2.7 million in Q1 2026, $9.7 million in Q4 2025, and $5.5 million in Q3 2025.